National cancer prevalence estimation in France.
In France, as in several other European countries, prevalence has to be estimated from the modelling of 2 of the 3 basic epidemiological measures of incidence, mortality, and survival. Since, in these countries, follow-up of cancer patients is only made in a few registries, we explored the feasibility of estimating prevalence in the absence of follow-up data. The method, which used only incidence and mortality, was validated on Danish data and applied to France. For this latter country, the estimation procedure is based on the recorded mortality data and an estimate of incidence for the entire country. It is applied to selected sites of cancer, which account for 80% of the estimated incidence. In 1992, the prevalence of patients who had such a diagnosis amounts to 538,000 women and 424, 000 men. The most frequent cancer sites are head and neck, breast, and large bowel. Most of the cancer sites present an increase in prevalence proportion between 1987 and 1992. The larger increases concern breast and prostate cancer.
Colonna
M
M
Registre des Cancers de l'Isère, Meylan, France. registre.cancer.isere@wanadoo.fr
Hedelin
G
G
Esteve
J
J
Grosclaude
P
P
Launoy
G
G
Buemi
A
A
Arveux
P
P
Tretarre
B
B
Chaplain
G
G
Lesec'h
J M
JM
Raverdy
N
N
Carli
P M
PM
Menegoz
F
F
Faivre
J
J
D000328:Adult; D000367:Age Factors; D000368:Aged; D000369:Aged, 80 and over; D001943:Breast Neoplasms / Q000453:epidemiology; D003718:Denmark; D018572:Disease-Free Survival; D005260:Female; D005602:France; D006258:Head and Neck Neoplasms / Q000453:epidemiology; D006801:Humans; D015994:Incidence; D007414:Intestinal Neoplasms / Q000453:epidemiology; D008297:Male; D008875:Middle Aged; D015233:Models, Statistical; D009369:Neoplasms / Q000453:epidemiology* / Q000401:mortality; D015995:Prevalence; D012042:Registries; D012737:Sex Factors